Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Cited by (116)

Items 101–116 of 116

1. Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors
   Deacon, Carolyn F · 2020 · Peptides
2. Beyond Glucagon-like Peptide-1: Is G-Protein Coupled Receptor Polypharmacology the Path Forward to Treating Metabolic Diseases?
   Sloop, Kyle W., Briere, Daniel A., Emmerson, Paul J., Willard, Francis S. · 2018 · ACS Pharmacology & Translational Science
3. Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)
   Berra, Cesare C., Rossi, Maria Chiara, Mirani, Marco, Ceccarelli Ceccarelli, Daniela, Romano, Cristina, Sassi, Lorenza, Peretti, Elena, Favacchio, Giuseppe, Pastore, Ida, Folini, Laura et al. · 2023 · Frontiers in Endocrinology
4. Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists
   Kelly, Clare A, Sipos, Jennifer A · 2025 · The Journal of Clinical Endocrinology & Metabolism
5. Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
   Di Folco, Ugo, Vallecorsa, Noemi, Nardone, Maria Rosaria, Pantano, Angelo Lauria, Tubili, Claudio · 2022 · Acta Diabetologica
6. The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications
   Jalleh, Ryan J., Talley, Nicholas J., Horowitz, Michael, Nauck, Michael A. · 2026 · Journal of Clinical Investigation
7. A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
   Ikushima, Ippei, Jensen, Lene, Flint, Anne, Nishida, Tomoyuki, Zacho, Jeppe, Irie, Shin · 2018 · Advances in Therapy
8. Effect of exendin (exenatide)—GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model
   Bulchandani, Deepti, Nachnani, Jagdish S., Herndon, Betty, Molteni, Agostino, Pathan, Muhammad H., Quinn, Tim, Hamdan, Hana A., Alba, Laura M., Graves, Leland · 2012 · European Journal of Pharmacology
9. Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
   Forst, Thomas, Pfützner, Andreas · 2013 · Expert Opinion on Pharmacotherapy
10. Long-term cost-effectiveness of two GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus in the Italian setting: Liraglutide versus lixisenatide
    Hunt, Barnaby, Kragh, Nana, McConnachie, Ceilidh C., Valentine, William J., Rossi, Maria C., Montagnoli, Roberta · 2017 · Clinical Therapeutics
11. Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture
    Holst, Jens Juul · 2021 · Diabetes
12. On the Effects of Glucagon-Like Peptide-1 on Blood Glucose Regulation in Normal and Diabetic Subjects
    HOLST, JENS JUUL, TOFT-NIELSEN, MAJ-BRIT, ØRSKOV, CATHRINE, NAUCK, MICHAEL, WILLMS, BEHREND · 2006 · Annals of the New York Academy of Sciences
13. Safety of injectable semaglutide for type 2 diabetes
    Peter, Rajesh, Bain, Steve C. · 2020 · Expert Opinion on Drug Safety
14. Impact of dose‐escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model‐based approach
    Papathanasiou, Theodoros, Strathe, Anders, Agersø, Henrik, Lund, Trine Meldgaard, Overgaard, Rune Viig · 2020 · Diabetes, Obesity and Metabolism
15. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity
    Patel, Dhiren, Smith, April · 2021 · Expert Review of Clinical Pharmacology
16. Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
    Viljoen, Adie, Bain, Stephen C. · 2023 · Endocrinology and Metabolism